KIF18A and CDK1 as combined therapeutic targets in cervical and endometrial carcinomas: based on bioinformatics analysis and in vitro experiments
Mengjie Wang, David Lukanovic, Fabio Barra, Aoli Lei · 2024
Read KIF18A and CDK1 as combined therapeutic targets in cervical and endometrial carcinomas: based on bioinformatics analysis and in vitro experiments by Mengjie Wang, David Lukanovic, Fabio Barra, Aoli Lei (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11730454.txt.
Description
Mengjie Wang, David Lukanovic, Fabio Barra, and Aoli Lei published a study in 2024 on two cancer drug targets. Some tumor cells have unstable chromosomes, which makes them weak to a class of blocking drugs. The team hunted for a partner gene that makes cervix and womb cancers even more open to those drugs.
Data from large cancer atlases pointed to a cell-cycle gene that was turned up high in both cancers. Its level tracked closely with the level of the first target gene. In lab tests, blocking the partner gene made cancer cells far more open to the first drug class. Using both blockers together slowed cell spread and pushed cells to die. The authors say the pair is a promising joint target for these cancers.
Catalog record
| CREATOR | Mengjie Wang, David Lukanovic, Fabio Barra, Aoli Lei |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |